Key Highlights
- 11.47% is the indicated pre-market gain in Quanome Technologies, Inc. (NASDAQ:QNME) on November 18, 2026, taking the price to USD 0.3324 from a calculated prior close of USD 0.2982, a calculated move of USD 0.0342.
- 2,048,083 in USD was Revenue for the quarter ended September 30, 2026, while the net loss was USD 664,270, a calculated loss equal to 32.4% of revenue, according to the filing.
- 669,954 in USD of cash at September 30, 2026 sits against USD 8,396,706 of total liabilities and USD 14,855,050 of total assets, and the filing carries going-concern language alongside an accumulated Deficit near USD 15.5 million.
- 6,541,236 new Quanome shares, about 19% of the pre-issuance count, are to be issued to QAI Labs in an all-stock deal valued at USD 5.0 million for about 5% of that company.
What Moved Quanome Technologies, Inc. (NASDAQ:QNME) in Pre-Market Trading on November 18, 2026 (+USD 0.0342, +11.47%)
The indicated pre-market price for Quanome Technologies, Inc. (NASDAQ:QNME) is USD 0.3324 on November 18, 2026, a pre-market move of +11.47%. The calculated prior close, the November 17, 2026 regular-session close, is USD 0.2982 (USD 0.3324 divided by 1.1147), and the calculated USD move is +USD 0.0342 (price minus prior close). Using the 34,969,416 shares stated on the latest quarterly filing cover, the calculated market Capitalization is about USD 11.62 million.
The Rationale: No New Catalyst Beyond the QAI Labs Stake for Quanome Technologies, Inc. (NASDAQ:QNME)
No company announcement dated November 18, 2026 was identified in published coverage. The most recent development found is an all-stock agreement dated November 4, 2026 and made public on November 9, 2026 under which Quanome will issue 6,541,236 unregistered shares to QAI Labs Ltd., about 19% of its stock before issuance and about 15.97% after, for 31,579 new QAI Labs shares, roughly 5% of that company. The negotiated value is USD 5.0 million, implying a QAI Labs Equity value near USD 100 million. QAI Labs is an early-stage, pre-commercial life sciences company with an artificial intelligence antibody platform and a laboratory in Sugar Land, Texas. Chief Executive Officer Yang Li said the Investment puts another quantum and AI strategy stream into execution. As general context, a nano-cap can also advance on thin order flow without fresh news.
Valuation, Liquidity and Risks for Quanome Technologies, Inc. (NASDAQ:QNME)
Quanome is a Holding Company whose subsidiaries mainly distribute pharmaceutical and medical products, largely in China. For the quarter ended September 30, 2026 it reported revenue of USD 2,048,083 and a net loss of USD 664,270. Cash was USD 669,954, total Assets were USD 14,855,050 and total liabilities were USD 8,396,706, a calculated liabilities-to-assets ratio of 56.5%. A related-party Loan of USD 3,799,980 was received in the quarter. The filing raises substantial doubt about the ability to continue as a Going Concern and cites an accumulated deficit of about USD 15.5 million. With a calculated Market Value under USD 100 million, the stock is a nano-cap, and the QAI Labs issuance adds a further 6,541,236 shares, which dilutes existing holders.
Where Things Stand
Quanome Technologies, Inc. (NASDAQ:QNME) is indicated up 11.47% in pre-market trading on November 18, 2026, at USD 0.3324, a calculated gain of USD 0.0342 from a prior close of USD 0.2982. No catalyst dated this morning was identified in published coverage. The latest quarter showed revenue of USD 2,048,083, a net loss of USD 664,270 and cash of USD 669,954, and the USD 5.0 million all-stock QAI Labs stake remains the main recent development. Going-concern language and dilution are central risks. This article is informational and is not investment advice.






Please wait processing your request...